ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
D형 간염 시장 규모는 최근 꾸준히 성장하고 있습니다. 2024년 7억 2,000만 달러에서 2025년에는 7억 6,000만 달러에 달하고, CAGR 4.3%를 나타낼 전망입니다. 실적기간의 성장은 제한된 치료 옵션, 유행 지역에서의 높은 유병률, B형 간염과의 동시 감염, 낮은 인지도와 진단률, 정부의 백신 접종 프로그램 등에 기인하고 있습니다.
D형 간염 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 CAGR(복합 연간 성장률) 4.2%를 나타내 8억 9,000만 달러로 성장할 전망입니다. 예측기간의 성장은 신규치료에 대한 상환정책 확대, 헬스케어 분야 투자 증가, 병용치료 채용률 상승, B형 간염 백신접종률 증가, 공중보건 이니셔티브 증가 등으로 인한 것으로 예측됩니다. 예측기간의 주요 동향으로는 분자진단 툴의 진보, 간질환 관리에 있어서의 맞춤형 의료로의 시프트, 신규 RNA 베이스 치료의 개발, D형 간염 치료에 있어서의 임상시험의 확대, 간염 관리에 있어서의 원격 의료의 이용 등을 들 수 있습니다.
δ형 간염이라고도 불리는 D형 간염은 D형 간염 바이러스(HDV)에 의해 유발되는 간 감염입니다. 바이러스성 간염 중에서 가장 심각한 것으로, 이미 B형 간염 바이러스(HBV)에 감염된 사람에게만 발병합니다. D형 간염 바이러스는 B형 간염 바이러스에 따라 복제와 생존을 수행하므로 중복 감염 또는 중복 감염이 됩니다.
D형 간염의 주요 유형은 급성과 만성입니다. 급성 D형 간염은 D형 간염 바이러스에 의해 야기되는 갑작스런 심각한 간 감염으로, 종종 증상이 빠르게 나타나고 간 합병증을 유발할 수 있습니다. 진단은 혈액 검사, 엘라스토그래피, 간 생검, 혈청학적 검사 및 기타 진단 기술을 포함한 다양한 방법으로 수행됩니다. D형 간염 의약품은 병원 약국, 소매 약국, 온라인 약국을 통해 유통되며 클리닉, 병원 및 기타 건강 관리 시설을 포함한 다양한 최종 사용자가 이용합니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 D형 간염 업계 세계 시장 규모, 지역 점유율, D형 간염 시장 점유율을 가진 경쟁업체, 상세한 D형 간염 시장 부문, 시장 동향, 비즈니스 기회 등 D형 간염 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 D형 간염 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 4.2%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 스위스에서 수입되는 페그 인터페론 치료제의 관세 관련 가격 상승은이 드문 질병에 대한 치료 가능성을 제한하고 취약한 집단에서 간경변으로의 진행을 억제하지 못할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
B형 간염의 유병률 상승은 향후 수년간 D형 간염 시장 성장을 이끌 것으로 예측됩니다. B형 간염은 간을 괴롭히고 황달, 권태감, 복통 등의 증상을 일으키는 바이러스 감염으로 방치하면 만성 간 질환이나 간암으로 이어질 수 있습니다. B형 간염 환자 증가는 무방비 성적 접촉, 주사 바늘 공유, 출산 시 모자 감염, 특정 지역에서 백신 접종률 부족 등의 요인 때문입니다. D형 간염은 B형 간염 바이러스의 복제에 의존하고, 그 표면 항원을 이용하여 간세포에 감염하기 때문에 양 바이러스에의 중복 감염이 간 질환의 진행에 크게 관여하고 있습니다. 예를 들어, 2023년 11월 미국 보건사회 복지부는 2022년 새로 보고된 만성 B형 간염 사례가 전년 대비 11% 증가했다고 보고했습니다. 그 결과 B형 간염의 유병률 증가가 D형 간염 시장 확대에 박차를 가하고 있습니다.
D형 간염 시장 주요 기업은 면역 효과를 향상시키고 바이러스에 대한 예방 효과를 장기간 지속시키기 위해 재조합 백신과 같은 혁신적인 제제의 개발에 주력하고 있습니다. 재조합 백신은 바이러스 단백질을 코딩하는 유전자를 박테리아 및 효모와 같은 숙주 유기체에 삽입함으로써 제조되며, 질병을 일으키지 않고 면역 반응을 자극하는 단백질의 생산을 가능하게 합니다. 예를 들어, 2022년 12월 미국의 생명공학기업인 VBI Vaccines Inc.는 캐나다 보건부로부터 18세 이상의 성인에서 알려진 모든 B형 간염 아형에 대한 적극적인 예방접종 백신인 PreHevbrio(3 항원 B형 간염 백신(유전자 재조합))의 승인을 받았습니다. 이 승인은 D형 간염의 원인인 델타균이 B형 간염 감염 없이는 존재할 수 없기 때문에 D형 간염의 예방에도 적용됩니다. 이번 결정은 PROTECT와 CONSTANT라는 두 가지 중요한 3상 임상시험의 좋은 결과를 바탕으로 한 항원인 Engerix-B 백신에 비해 PreHevbrio가 더 높은 혈청 방어율을 보였습니다.
2023년 10월, 미국의 바이오 의약품 회사 길리아드 사이언시스는 차세대 항바이러스 요법의 개발을 진행하기 위해 어셈블리 바이오사이언시스와 제휴했습니다. 이 제휴는 B형 간염, 헤르페스 바이러스, D형 간염을 비롯한 심각한 바이러스 감염에 대한 혁신적인 치료법의 창출을 목표로 합니다. Assembly Biosciences Inc.는 미국을 기반으로 하는 생명공학 기업으로, 특히 B형 간염 바이러스(HBV) 및 헤르페스 바이러스와 같은 심각한 바이러스성 질환을 표적으로 하는 소분자 치료제의 개발에 특화되어 있습니다.
D형 간염 시장은 임상·진단 서비스, 공중위생·계발 캠페인, 연구개발 서비스, 치료 서비스 등의 서비스를 제공하는 사업체가 얻는 수익으로 구성됩니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. D형 간염 시장에는 항바이러스제물, 인터페론 요법, 핵산 중합체, 간 이식 서비스, 진단 검사 등의 판매도 포함됩니다. 이 시장의 가치는 '팩토리 게이트(공장 출하 시)' 가치입니다. 즉, 제품 제조업체 또는 제조업체가 다른 기업(강하 제조업체, 도매업체, 유통업체, 소매업체 포함) 또는 직접 최종 고객에게 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 D형 간염 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 D형 간염 시장 : 성장률 분석
세계의 D형 간염 시장 실적 : 규모와 성장(2019-2024년)
세계의 D형 간염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 D형 간염 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 D형 간염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
급성
만성
세계의 D형 간염 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
혈액 검사
탄성영상술
간 생검
혈청학적 검사
기타 진단
세계의 D형 간염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 D형 간염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
클리닉
병원
기타 최종 사용자
세계의 D형 간염 시장 : 급성 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
자가 제한성 급성 D형 간염
중증 급성 D형 간염
세계의 D형 간염 시장 : 만성 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
보상성 만성 D형 간염
비보상성 만성 D형 간염
제7장 지역별/국가별 분석
세계의 D형 간염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 D형 간염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
D형 간염 시장 : 경쟁 구도
D형 간염 시장 : 기업 프로파일
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
GSK plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Gilead Sciences Inc.
Viatris Inc
VBI Vaccines Inc
Alnylam Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Dynavax Technologies Corporation
Echosens SA
Arbutus Biopharma Corporation
PROBIOMED SA de CV
Assembly Biosciences Inc.
Replicor Inc.
Eiger BioPharmaceuticals Inc
Bluejay Therapeutics Inc
Janssen Pharmaceuticals Inc.
Transgene SA
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
D형 간염 시장(2029년) : 새로운 기회를 제공하는 국가
D형 간염 시장(2029년) : 새로운 기회를 제공하는 부문
D형 간염 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Hepatitis D, also referred to as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is regarded as the most severe form of viral hepatitis and occurs exclusively in individuals already infected with the hepatitis B virus (HBV). The hepatitis D virus relies on the hepatitis B virus for replication and survival, making it either a co-infection or a superinfection.
The primary types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by the hepatitis D virus, often leading to rapid-onset symptoms and potential liver complications. Diagnosis is conducted through various methods, including blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Medications for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, including clinics, hospitals, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The hepatitis D market research report is one of a series of new reports from The Business Research Company that provides hepatitis D market statistics, including the hepatitis D industry global market size, regional shares, competitors with the hepatitis D market share, detailed hepatitis D market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis D industry. This hepatitis D market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hepatitis d market size has grown steadily in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to limited treatment options, high prevalence in endemic regions, co-infection with hepatitis B, low awareness and diagnosis rates, and government vaccination programs.
The hepatitis d market size is expected to see steady growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to expansion of reimbursement policies for novel therapies, and rising investment in the healthcare sector, rising adoption of combination treatments, increasing hepatitis B vaccination coverage, and growing public health initiatives. Major trends in the forecast period include advancements in molecular diagnostic tools, shift toward personalized medicine for liver disease management, development of novel RNA-based therapies, expansion of clinical trials for hepatitis D treatments, and use of telemedicine for hepatitis management.
The forecast of 4.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff-related price increases for pegylated interferon therapies imported from Switzerland may limit treatment availability for this rare condition, leading to unchecked progression to cirrhosis in vulnerable populations. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of hepatitis B is expected to drive the growth of the hepatitis D market in the coming years. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increasing number of hepatitis B cases is attributed to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D depends on the hepatitis B virus for replication, using its surface antigen to infect liver cells, making co-infection with both viruses a significant factor in liver disease progression. For example, in November 2023, the US Department of Health and Human Services reported an 11% rise in newly reported chronic hepatitis B cases in 2022 compared to the previous year. As a result, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.
Leading companies in the hepatitis D market are focusing on developing innovative formulations such as recombinant vaccines to improve immunization efficacy and provide long-lasting protection against the virus. Recombinant vaccines are produced by inserting a gene encoding a viral protein into a host organism, such as bacteria or yeast, allowing the production of the protein to stimulate an immune response without causing the disease. For instance, in December 2022, VBI Vaccines Inc., a US-based biotechnology company, received approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], a vaccine for active immunization against all known subtypes of hepatitis B in adults aged 18 and older. This approval also extends to hepatitis D prevention, as the delta agent responsible for hepatitis D cannot exist without a hepatitis B infection. The decision was based on positive results from two pivotal Phase 3 clinical studies, PROTECT and CONSTANT, which demonstrated higher seroprotection rates with PreHevbrio compared to the single-antigen Engerix-B vaccine.
In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to advance the development of next-generation antiviral therapies. This collaboration aims to create innovative treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc. is a US-based biotechnology company specializing in the development of small-molecule therapeutics targeting serious viral diseases, particularly hepatitis B virus (HBV) and herpes viruses.
Major players in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, and Biorex Diagnostics Ltd.
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis D report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hepatitis D market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hepatitis D Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hepatitis d market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hepatitis d ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis d market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Acute; Chronic
2) By Diagnosis: Blood Tests; Elastography; Liver Biopsy; Serologic Testing; Other Diagnosis
3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online Pharmacies
4) By End-Users: Clinic; Hospital; Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D; Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D; Decompensated Chronic Hepatitis D
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hepatitis D Market Characteristics
3. Hepatitis D Market Trends And Strategies
4. Hepatitis D Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Hepatitis D Growth Analysis And Strategic Analysis Framework
5.1. Global Hepatitis D PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hepatitis D Market Growth Rate Analysis
5.4. Global Hepatitis D Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hepatitis D Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hepatitis D Total Addressable Market (TAM)
6. Hepatitis D Market Segmentation
6.1. Global Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute
Chronic
6.2. Global Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Elastography
Liver Biopsy
Serologic Testing
Other Diagnosis
6.3. Global Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital pharmacies
Retail pharmacies
Online Pharmacies
6.4. Global Hepatitis D Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinic
Hospital
Other End Users
6.5. Global Hepatitis D Market, Sub-Segmentation Of Acute, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Self-limiting Acute Hepatitis D
Severe Acute Hepatitis D
6.6. Global Hepatitis D Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Compensated Chronic Hepatitis D
Decompensated Chronic Hepatitis D
7. Hepatitis D Market Regional And Country Analysis
7.1. Global Hepatitis D Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hepatitis D Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Hepatitis D Market
8.1. Asia-Pacific Hepatitis D Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hepatitis D Market
9.1. China Hepatitis D Market Overview
9.2. China Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hepatitis D Market
10.1. India Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hepatitis D Market
11.1. Japan Hepatitis D Market Overview
11.2. Japan Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hepatitis D Market
12.1. Australia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hepatitis D Market
13.1. Indonesia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hepatitis D Market
14.1. South Korea Hepatitis D Market Overview
14.2. South Korea Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hepatitis D Market
15.1. Western Europe Hepatitis D Market Overview
15.2. Western Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hepatitis D Market
16.1. UK Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Hepatitis D Market
17.1. Germany Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hepatitis D Market
18.1. France Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hepatitis D Market
19.1. Italy Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hepatitis D Market
20.1. Spain Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hepatitis D Market
21.1. Eastern Europe Hepatitis D Market Overview
21.2. Eastern Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hepatitis D Market
22.1. Russia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hepatitis D Market
23.1. North America Hepatitis D Market Overview
23.2. North America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hepatitis D Market
24.1. USA Hepatitis D Market Overview
24.2. USA Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Hepatitis D Market
25.1. Canada Hepatitis D Market Overview
25.2. Canada Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hepatitis D Market
26.1. South America Hepatitis D Market Overview
26.2. South America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hepatitis D Market
27.1. Brazil Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hepatitis D Market
28.1. Middle East Hepatitis D Market Overview
28.2. Middle East Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hepatitis D Market
29.1. Africa Hepatitis D Market Overview
29.2. Africa Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hepatitis D Market Competitive Landscape And Company Profiles
30.1. Hepatitis D Market Competitive Landscape
30.2. Hepatitis D Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis
31. Hepatitis D Market Other Major And Innovative Companies
31.1. Gilead Sciences Inc.
31.2. Viatris Inc
31.3. VBI Vaccines Inc
31.4. Alnylam Pharmaceuticals Inc.
31.5. Arrowhead Pharmaceuticals Inc.
31.6. Dynavax Technologies Corporation
31.7. Echosens S.A
31.8. Arbutus Biopharma Corporation
31.9. PROBIOMED SA de CV
31.10. Assembly Biosciences Inc.
31.11. Replicor Inc.
31.12. Eiger BioPharmaceuticals Inc
31.13. Bluejay Therapeutics Inc
31.14. Janssen Pharmaceuticals Inc.
31.15. Transgene SA
32. Global Hepatitis D Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Hepatitis D Market
34. Recent Developments In The Hepatitis D Market
35. Hepatitis D Market High Potential Countries, Segments and Strategies
35.1 Hepatitis D Market In 2029 - Countries Offering Most New Opportunities
35.2 Hepatitis D Market In 2029 - Segments Offering Most New Opportunities
35.3 Hepatitis D Market In 2029 - Growth Strategies
